A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease

Bibliography

• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Niewoehner DE. TORCH and UPLIFT: what has been learned from the COPD “mega-trials”? COPD 2009;6:1-3
   PubMedGoogle Scholar
• Vestbo J, Vogelmeier C, Small M, et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med 2014;105:729-36
   Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD 2015). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf [Last accessed 13 February 2015]
   Google Scholar
• European Medicines Agency (EMA). Seretide diskus summary of product characteristics (SmPC). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Seretide_Diskus_6_13/WC500013534.pdf
   Google Scholar
• Montuschi P, Malerba M, Santini G, et al. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today 2014;19:1928-35
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001-6
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-36
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699-708
   PubMed Web of Science ®Google Scholar
• Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:855-9
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Murray HE, Skeans M, et al. Skin manifestations of inhaled corticosteroids in COPD patients: results from lung health study II. Chest 2004;126:1123-33
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-13
   PubMed Web of Science ®Google Scholar
• Dong YH, Chang CH, Lin Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest 2014;145:1286-97
   PubMed Web of Science ®Google Scholar
• Ernst P, Baltzan M, Deschênes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-74
   PubMed Web of Science ®Google Scholar
• Flynn RW, MacDonald TM, Hapca A, et al. Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir Res 2014;15:141
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22:92-100
   PubMedGoogle Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45:525-37
   PubMed Web of Science ®Google Scholar
• Izquierdo Alonso JL, Rodríguez Glez-Moro JM. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch Bronconeumol 2012;48:207-12
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011;47:271-3
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42
   PubMed Web of Science ®Google Scholar
• Price D, Rigazio A, Postma D, et al. Blood eosinophilia and the number of exacerbations in COPD patients (Abstract). Eur Respir J 2015;44(Suppl 58):4416
   Google Scholar
• Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24
   PubMed Web of Science ®Google Scholar
• Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol study group. Ann Allergy Asthma Immunol 1999;82:383-9
   PubMed Web of Science ®Google Scholar
• van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207-12
   PubMed Web of Science ®Google Scholar
• Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013;20:1477-95
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;11:CD003794
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-65
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 µg versus salmeterol 50 µg after chronic obstructive pulmonary disease exacerbation. Respir Res 2014;15:105
   PubMed Web of Science ®Google Scholar
• Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011;65:764-74
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12:27-34
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23
   PubMed Web of Science ®Google Scholar
• Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014;312:1114-21
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136:1029-38
   PubMed Web of Science ®Google Scholar
• Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014;3:CD010844
   PubMed Web of Science ®Google Scholar
• Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem 2013;20:1464-76
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;5:CD007891
   PubMedGoogle Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15:123
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752-60
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 µg in COPD. Respir Med 2013;107:1538-46
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014;14:178
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J 2015;45:969-79
   PubMed Web of Science ®Google Scholar
• Bateman ED, Mahler DA, Vogelmeier CF, et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014;8:357-79
   PubMed Web of Science ®Google Scholar
• Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134:255-62
   PubMed Web of Science ®Google Scholar
• Magnussen H, Paggiaro P, Schmidt H, et al. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med 2012;106:1413-20
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60
   PubMed Web of Science ®Google Scholar
• Bateman ED, Vogelmeier C, Chen H, et al. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study (Abstract). Chest 2014;145(3_Meeting abstracts):409A
   Web of Science ®Google Scholar
• Donohue J, Worsley S, Zhu CQ, et al. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations (Abstract). Chest 2014;146(4_Meeting abstracts):73A
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. NCT01817764 (DB2114930). A study to compare the efficacy and safety of umeclidinium/vilanterol and fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD) 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01817764 [Last accessed 5 December 2013]
   Google Scholar
• Clinicaltrials.gov. NCT01879410 (DB2114951). A study to compare the efficacy and safety of umeclidinium/vilanterol and fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD) 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01879410 [Last accessed 5 December 2013]
   Google Scholar
• Donohue J, Worsley S, Zhu C-Q, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015;109:870-81
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J COPD 2015;10:1015-26
   Google Scholar
• Clinicaltrials.gov. NCT01782326 (FLAME; A2318). QVA vs. salmeterol/fluticasone, 52-week exacerbation study 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01782326 [Last accessed 5 December 2013]
   Google Scholar
• Clinicaltrials.gov. NCT02164513. A study comparing the efficacy, safety and tolerability of fixed dose combination (FDC) of FF/UMEC/VI with the FDC of FF/VI and UMEC/VI; administered once-daily via a dry powder inhaler (DPI) in subjects with chronic obstructive pulmonary disease (COPD) 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT02164513 [Last accessed 4 December 2014]
   Google Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research Division of Pulmonary and Allergy Drug Products (HFD-570) Backgrounder for sNDA 21-077 - Advair Diskus 250/50, Advair Diskus 500/50. Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3830b1_02_Glaxo-ADVAIR.pdf [Last accessed 20 January 2015]
   Google Scholar
• European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP) assessment report. Relvar Ellipta. international non-proprietary name: fluticasone furoate/ vilanterol. Procedure No. EMEA/H/C/002673/0000 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002673/WC500157635.pdf [Last accessed 15 December 2014]
   Google Scholar
• Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 2014;9:1163-86
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014;50(Suppl 1):1-16
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015;21:74-9
   PubMed Web of Science ®Google Scholar
• Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014;44:341-50
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385:857-66
   PubMed Web of Science ®Google Scholar
• McGarvey L, Lee AJ, Roberts J, et al. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med 2015;109:228-37
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Criee CP, et al. Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort (Abstract). Eur Respir J 2014;44(Suppl 58):P930
   Google Scholar
• Bleecker ER, Emmett A, Crater G, et al. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008;21:682-8
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Overbeek SE, Schouten JP, et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J 1993;6:868-76
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71
   PubMed Web of Science ®Google Scholar
• Leuppi JD, Tandjung R, Anderson SD, et al. Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther 2005;18:83-8
   PubMed Web of Science ®Google Scholar
• Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1773-7
   PubMed Web of Science ®Google Scholar
• Dummer JF, Epton MJ, Cowan JO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009;180:846-52
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Li H, Rubin DB, et al. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013;3:e001838
   Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71
   PubMed Web of Science ®Google Scholar
• Liesker JJ, Bathoorn E, Postma DS, et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med 2011;105:1853-60
   PubMed Web of Science ®Google Scholar
• Freeman D, Price D, Jones R, et al. Predicting patients with COPD who are likely to exacerbate - is it feasible in primary care? (Abstracts from the respiratory effectiveness group’s inaugural summit, The Royal College of General Practitioners, London, 28-29 June 2014). NPJ Prim Care Respir Med 2014;24:Abstract 06
   Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-700
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res 2007;8:93
   PubMed Web of Science ®Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999;93:161-6
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-63
   PubMed Web of Science ®Google Scholar
• Kardos P. Methodological issues in therapeutic trials of COPD. Eur Respir J 2009;33:443-4
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:927-33
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94
   PubMed Web of Science ®Google Scholar
• Reilly JJ. Stepping down therapy in COPD. N Engl J Med 2014;371:1340-1
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014;15:77
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 2014;44:1548-56
   PubMed Web of Science ®Google Scholar
• Haughney J, Gruffydd-Jones K, Roberts J, et al. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014;43:993-1002
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MÁ, Soler-Cataluña JJ, Donat SY, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140:1130-7
   PubMed Web of Science ®Google Scholar
• O’Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635-42
   PubMed Web of Science ®Google Scholar
• Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-7
   PubMed Web of Science ®Google Scholar
• Singh D, Worsley S, Zhu C, et al. Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations (Poster P290). European Respiratory Society International Congress; 6-10 September 2014; Munich, Germany
   Google Scholar
• Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013;1:43-50
   PubMed Web of Science ®Google Scholar
• Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186:975-81
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013;42:636-46
   PubMed Web of Science ®Google Scholar
• Agusti A, Hurd S, Jones P, et al. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 2013;42:1391-401
   PubMed Web of Science ®Google Scholar